Exchange: NASDAQ·Updated 07:30 PM EST

ACIU News

News
all
press releases
Summit Stock Falls on FDA Rejection for Lung Cancer Drug
SMMT's shares plunge 20% as the FDA issues a CRL for ivonescimab, citing insufficient overall survival evidence despite positive progression-free survival results.
Zacks
Summit Stock Falls on FDA Rejection for Lung Cancer Drug
SMMT's shares plunge 20% as the FDA issues a CRL for ivonescimab, citing insufficient overall survival evidence despite positive progression-free survival results.
Zacks
More News
KOD reports a wider-than-expected Q3 loss, while positive phase III results for Zenkuda and pipeline progress fuel its upcoming regulatory plans.
Zacks
CorMedix beats Q3 estimates, but DefenCath pricing pressure hurts sales. Rezzayo progress and the planned Heron acquisition shape its 2027 outlook.
Zacks
Altimmune's Q3 loss is wider than estimates as rising R&D costs weigh on earnings, while pemvidutide advances across MASH, AUD and ALD programs.
Zacks
Replimune shares surge 80% as Tudriqev's commercial launch gains traction, earnings beat expectations and pipeline progress strengthens growth prospects.
Zacks
Aura completes phase III enrollment for bel-sar, with pivotal data expected in 2027 and additional ocular cancer programs expanding its growth potential.
Zacks
ZTS' Cytopoint Plus secures a USDA license, offering dogs with allergic dermatitis 75 days of itch relief and a longer interval between injections.
Zacks
Beam Therapeutics reports positive BEACON study results for risto-cel in sickle cell disease, paving the way for a potential FDA filing by year-end 2026.
Zacks
AC Immune (ACIU) delivered earnings and revenue surprises of +27.27% and +299.42%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Insmed shares slide after CFO Sara Bonstein's surprise exit, though the company reaffirms 2026 revenue guidance for Brinsupri and Arikayce.
Zacks

Advertisement|Remove ads.